Original article by Tim Binsted
The Australian Financial Review – Page: 15 : 24-Jun-15

Crescent Capital has paid $A105m for the pathology assets of Australian-listed Healthscope, with the deal comprising a cash component of $A92.5m and a $A12.5m promissory note. Healthscope CEO Robert Cooke says the deal will allow the group to focus on its core business of private hospitals. In addition to Healthscope’s pathology laboratories and collection centres, the private equity firm will also buy a portfolio of six skin clinic.

CORPORATES
HEALTHSCOPE LIMITED – ASX HSO, CRESCENT CAPITAL PARTNERS LIMITED, SONIC HEALTHCARE LIMITED – ASX SHL, PRIMARY HEALTH CARE LIMITED – ASX PRY, TPG CAPITAL LP, THE CARLYLE GROUP, CLSA AUSTRALIA PTY LTD, NATIONAL DENTAL CARE PTY LTD, LIFEHEALTHCARE GROUP LIMITED – ASX LHC, NATIONAL HEARING CARE LIMITED, SOUTHERN SUN SKIN CANCER CLINICS